Skip to main content

Table 1 Demographic and clinical data of patients and controls. ANOVA was used for the comparisons of variables among the five groups

From: Sleep dysregulation, memory impairment, and CSF biomarkers during different levels of neurocognitive functioning in Alzheimer’s disease course

Demographic and clinical data

Subjects/patients

Controls

Total sample (n = 258) (including controls)

F

ANOVA p

Post hoc comparisons

(2) SCI (n = 54)

(3) MCI (n = 59)

(4) m-AD (n = 56)

(5) ms-AD (n = 48)

(1) CN (n = 41)

Gender

 Male, N (%)

24 (44.4)

28 (47.4)

21 (37.5)

19 (39.6)

20 (48)

112 (43)

   

 Female, N (%)

30 (55.6)

31 (52.6)

35 (62.5)

29 (60.4)

21 (52)

146 (57)

   

Age, mean ± SD (range)

64.94 ± 8.75 (44–80)

67.42 ± 8.43 (44–80)

69.93 ± 7.27 (55–83)

71.71 ± 7.19 (53–82)

67.17 ± 9.83 (44–83)

68.21 ± 8.55 (44–83)

5.13

.001

2 < 4,5

MMSE score, mean ± SD

29.11 ± 1.00 (27–30)

25.85 ± 1.51 (23–29)

24.45 ± 1.85 (21–27)

15.40 ± 3.21 (4–20)

29.20 ± 0.90 (27–30)

24.81 ± 5.22 (4–30)

433.98

.000

5 < 4 < 3 < 2,1

CSF biomarkers

 T-tau (pg/mL)

253.67 ± 163.87 (92–1117)

569.59 ± 363.82 (160–1876)

632.07 ± 243.18 (116–1190)

744.44 ± 254.34 (222–1245)

234.22 ± 64.42 (116–402)

496.26 ± 317.21 (92–1876)

41.87

.000

1,2 < 3 < 5; 1,2 < 3,4

 P-tau (pg/mL)

42.37 ± 23.60 (4–156)

85.41 ± 49.04 (32–240)

88.75 ± 35.15 (31–189)

100.77 ± 45.42 (34–235)

42.34 ± 11.76 (22–85)

73.14 ± 43.60 (4–240)

27.80

.000

1,2 < 3,4,5

 Aβ42 (pg/mL)

666.44 ± 257.75 (259–1123)

320.22 ± 98.76 (132–460)

275.84 ± 68.42 (82–440)

270.67 ± 90.95 (123–463)

854.66 ± 182.15 (582–1197)

458.76 ± 275.60 (82–1197)

140.48

.000

5,4,3 < 2 < 1

Neuropsychological tests

    

 RAVLT-I score, mean ± SD

44.31 ± 3.91 (39–54)

23.27 ± 2.95 (18–28)

18.30 ± 3.36 (11–23)

11.54 ± 2.98 (7–16)

46.20 ± 4.44 (39–53)

28.06 ± 14.04 (7–54)

956.40

.000

5 < 4 < 3 < 2,1

 RAVLT-D score, mean ± SD

9.87 ± 2.01 (7–14)

2.80 ± 1.23 (0–4)

1.57 ± 1.17 (0–4)

1.25 ± 1.02 (0–3)

10.46 ± 1.58 (8–13)

4.94 ± 4.25 (0–14)

495.32

.000

5,4 < 3 < 2,1

Polysomnography

 TST (min)

348.070 ± 79.86 (161.50–580)

349.37 ± 53.65 (146.5–415)

318.82 ± 44.16 (220–430)

252.93 ± 47.77 (149.3–361.8)

367.22 ± 60.93 (135–444)

327.36 ± 69.88 (135–580)

28.19

.000

5 < 4 < 2,3,1

 SE (%)

77.80 ± 13.53 (31.5–96.4)

78.50 ± 10.55 (50.4–94)

74.4 ± 6.71 (59.4–89)

67.76 ± 9.21 (36.5–91.5)

89.15 ± 2.27 (84.3–92.4)

77.16 ± 11.42 (31.5–96.4)

29.64

.000

5 < 4,3 < 1; 5 < 2 < 1

 SL (min)

23.30 ± 64.62 (0.30–343)

27.73 ± 36.02 (2–150)

20.46 ± 16.63 (1–76)

24.27 ± 23.70 (1–122)

12.95 ± 6.34 (5–36)

22.23 ± 36.67 (0.30–343)

1.07

.372

NS

 REML (min)

119.49 ± 78.97 (40–412)

135.25 ± 82.13 (12–330)

179.64 ± 102.92 (12–424)

143.57 ± 51.32 (27.5–220)

103.83 ± 16.16 (77–143)

138.14 ± 79.00 (12–424)

7.27

.000

1 < 3; 1,2 < 4

 N1 (%)

16.07 ± 7.00 (3.8–34)

21.87 ± 8.18 (7.5–34.6)

31.05 ± 8.61 (12.2–45.7)

33.81 ± 11.00 (10.4–64.1)

15.37 ± 3.35 (10–21)

23.84 ± 10.95 (3.80–64.1)

53.50

.000

1,2 < 3 < 4,5

 N2 (%)

55.10 ± 7.66 (34–72.6)

52.12 ± 8.18 (31.8–67)

51.35 ± 9.41 (31.8–71.7)

54.67 ± 9.02 (28.10–76)

50.90 ± 3.45 (44–59)

52.86 ± 8.11 (28.10–76)

2.92

.022

3 < 2

 N3 (%)

16.29 ± 6.64 (6.5–29.3)

16.14 ± 5.85 (4–31.4)

11.18 ± 7.70 (0.80–28.7)

6.93 ± 5.18 (0–22)

17.83 ± 1.46 (14–21)

13.65 ± 7.08 (0–31.4)

28.11

.000

5 < 4 < 3,2,1

 REM (%)

12.56 ± 5.62 (0–25.5)

9.37 ± 4.99 (0–20)

6.41 ± 3.94 (0.80–16)

4.60 ± 3.69 (0–12.20)

15.90 ± 2.96 (11–22)

9.54 ± 5.86 (0–25.5)

49.41

.000

5 < 4 < 3 < 2 < 1

 WASO (min)

99.48 ± 67.54 (17.5–351.2)

78.54 ± 56.61 (− 69.19–221)

92.26 ± 42.82 (− 8.52–193.45)

97.63 ± 47.88 (4.74–240.72)

31.95 ± 12.42 (3.74–53.23)

82.05 ± 55.09 (− 69.19–351.20)

13.54

.000

1 < 3,4,5,2

 TIB

451.31 ± 103.92 (274–964)

446.22 ± 51.35 (290–7-600)

431.55 ± 66.51 (269–573.33)

374.83 ± 58.69 (239–498)

412.13 ± 67.27 (146.7–498.9)

425.40 ± 76.53 (146.7–964.15)

9.35

.000

5 < 2; 5 < 3; 5 < 4

  1. N frequency, % percentage, Min-Max extreme value, SD standard deviation. The numbers in parentheses in group names refer to the numbers used in illustrating statistically significant differences
  2. Abbreviations: MMSE Mini-Mental State Examination, T-tau total tau, P-tau phosphorylated tau, 42 β-amyloid42, RAVLT-I Immediate Recall – Rey Auditory Verbal Learning Test, RAVLT-D Differite Recall – Rey Auditory Verbal Learning Test, TST total sleep time, SE sleep efficiency, SL sleep onset latency, REML REM sleep latency, N1 stage 1 of non-REM sleep, N2 stage 2 of non-REM sleep, N3 stage 3 of non-REM sleep, REM REM sleep, WASO wakefulness after sleep onset, TIB time in bed, NS not significant, AD Alzheimer’s disease, mAD mild Alzheimer’s disease, msAD moderate-severe Alzheimer’s disease, MCI mild cognitive impairment, SCI subjective cognitive impairment, CN cognitively normal